Lupin’s shares surged by 2.2% following tentative U.S. FDA approval for its generic HIV treatment, Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets. This positions Lupin to enter a significant U.S. market segment with estimated annual sales of $16.237 billion. The drug, a generic version of Gilead Sciences’ Biktarvy, will be manufactured at Lupin’s Nagpur facility.